ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1964

The Risk of Hydroxychloroquine Toxic Retinopathy and Its Risk Factors in the Treatment of Rheumatic Diseases: A Systematic Review

April Jorge1, Sharan K. Rai2 and Hyon K. Choi2, 1Rheumatology, Allergy, and Immunology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, 2Division of Rheumatology, Allergy, and Immunology, Massachusetts General Hospital, Harvard Medical School, Boston, MA

Meeting: 2017 ACR/ARHP Annual Meeting

Date of first publication: September 18, 2017

Keywords: Data analysis, Hydroxychloroquine, medication side effects and rheumatic disease

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Tuesday, November 7, 2017

Title: Epidemiology and Public Health Poster III: Rheumatic Disease Risk and Outcomes

Session Type: ACR Poster Session C

Session Time: 9:00AM-11:00AM

Background/Purpose:

Hydroxychloroquine (HCQ) is widely used in the treatment of systemic lupus erythematosus (SLE), rheumatoid arthritis (RA), and other rheumatic diseases. While generally well-tolerated and regarded as one of the safest treatment options for these conditions, the major long-term risk is vision-threatening retinopathy. The risk of retinopathy has been shown to vary by amount of HCQ exposure. However, the true risk of HCQ retinopathy remains unclear, and clinical consensus may be lacking between US and European rheumatology and ophthalmology societies regarding the safe dosing of HCQ. Our objective was to systematically review and appraise current evidence of the risk of HCQ retinopathy and its purported risk factors.

Methods:

We conducted a systematic search of MEDLINE and EMBASE databases through June 2017. Inclusion criteria were: 1) study sample including individuals treated with HCQ; 2) study design of either retrospective or prospective study with a comparator group; and 3) retinopathy outcomes reported. The primary outcome was HCQ retinopathy incidence and/or prevalence, and other data of interest included measures of HCQ exposure (e.g., mean daily dose, mean cumulative dose, and mean duration of HCQ use), method of HCQ retinopathy ascertainment, risk factors for HCQ retinopathy, and rheumatologic diagnosis.

Results:

We identified 3,236 unique citations. Of these, 28 studies were ultimately included in the systematic review. Ten studies (all published in 2014 or later) reported current standard-of-care screening modalities (e.g., Humphreys visual fields (VF) and spectral domain-optical coherence tomography (SD-OCT)). Eleven studies reported the use of only older screening modalities (e.g., funduscopic, visual acuity, and color vision assessments), 5 studies used ophthalmologist reports of toxicity, and 2 studies did not describe a method of retinopathy ascertainment. Of the 10 recent studies, HCQ retinopathy risk estimates ranged from 2.9-30.5%, with 2 studies reporting a risk of 10% or higher. Of the 18 older studies, HCQ retinopathy risk estimates ranged from 0.5%-21%, with 2 studies reporting a risk over 5%. Twelve studies examined predictors of retinopathy. Of these, 3 found age and 1 found CKD to be predictors of retinopathy. Duration of HCQ use, cumulative dose of HCQ, and daily dose of HCQ were associated with HCQ retinopathy risk in 5, 4, and 2 studies, respectively. Underlying rheumatologic disease (e.g., SLE versus RA) did not impact retinopathy risk. The mean daily HCQ doses varied from 3.1mg/kg/day to 8.4mg/kg/day for the overall cohorts exposed to HCQ, with some studies reporting dose per ideal body weight and others reporting actual body weight.

Conclusion:

This is the first systematic review on the risk of toxic retinopathy secondary to HCQ. The risk estimate of HCQ retinopathy varies considerably in the published literature, with increased risk estimates reported in recent studies. More recent ophthalmologic screening methods including SD-OCT have increased sensitivity to detect earlier stages of retinopathy. Prospective studies are urgently needed to accurately characterize the risk and risk factors of HCQ retinopathy.

 


Disclosure: A. Jorge, None; S. K. Rai, None; H. K. Choi, Selecta, Horizon, 5,AstraZeneca, 2.

To cite this abstract in AMA style:

Jorge A, Rai SK, Choi HK. The Risk of Hydroxychloroquine Toxic Retinopathy and Its Risk Factors in the Treatment of Rheumatic Diseases: A Systematic Review [abstract]. Arthritis Rheumatol. 2017; 69 (suppl 10). https://acrabstracts.org/abstract/the-risk-of-hydroxychloroquine-toxic-retinopathy-and-its-risk-factors-in-the-treatment-of-rheumatic-diseases-a-systematic-review/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2017 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/the-risk-of-hydroxychloroquine-toxic-retinopathy-and-its-risk-factors-in-the-treatment-of-rheumatic-diseases-a-systematic-review/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology